unknown
Stage
About
Aitiologic develops a multi-modal liquid biopsy platform (aitios®) that analyzes genomic, epigenomic, and fragmentomic signals from cell-free DNA in blood for tissue-resolved diagnostics. Its initial application is a first-trimester non-invasive prenatal and preeclampsia test for early risk stratification.
Explore Aitiologic's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.